AUSTIN, TEXAS, May 16, 2018 – Siva Therapeutics (“Siva”) is pleased to announce that it has received Notice of Allowance from the US Patent and Trademark Office on all 24 claims in its Patent Application number 14/567,077 entitled “Multifunctional Radiation Delivery Apparatus and Method.”
This patent covers many aspects of the design and use of the “smart” SivaLum™ light-emitting diode-based light engine for delivering safe, high intensity infrared light over a large area as a key element of Siva’s Targeted Hyperthermia™ photothermal cancer therapy. Together with SivaRods™ precision polymer-coated gold nanorods, the SivaLum is part of an optimized system for delivering Targeted Hyperthermia to solid tumors. The term “radiation” in the patent title refers broadly to electromagnetic radiation, including infrared light; Siva’s technology involves no ionizing radiation, which has harmful effects on humans.
“The light engine patent is an important milestone for Siva.” said Len Pagliaro, PhD, CEO of Siva. “It confirms our belief that Siva’s systems approach to implementing practical photothermal therapy has been the best path to follow. Other efforts that have used sub-optimal existing lasers for illumination have not met with the success of our custom-designed and optimized SivaLum light engine that has been paired with optimized SivaRods to form an integral system to deliver Targeted Hyperthermia. Together with our pilot-scale SivaRod manufacturing, the SivaLum places us a step closer to the clinic for first-in-human studies.”
About Siva Therapeutics Inc
Siva Therapeutics Inc is developing Targeted Hyperthermia™, a photothermal cancer therapy, which uses therapeutic heat to treat solid cancers. The heat is delivered to tumors by infrared light that is absorbed by SivaRods™ gold nanorods in the tumor and re-emitted as heat. The size, shape, and surface chemistry of the nanorods target the leaky vasculature of solid tumors, and the selective thermal sensitivity of tumor tissue enables the therapy to deliver clean margins. Targeted Hyperthermia promises to be extremely safe, effective, minimally invasive, competitive in cost, and a valuable adjunct to drug therapy and other cancer treatments. Siva’s initial clinical targets include melanoma and head & neck cancer.
Contact us at email@example.com or visit: www.sivatherapeutics.com
View a .pdf of this press release here.